Conformis Inc logo

CFMS - Conformis Inc Share Price

$1.53 -0.1  -6.7%

Last Trade - 04/08/21

Small Cap
Market Cap £215.1m
Enterprise Value £158.0m
Revenue £47.5m
Position in Universe 4278th / 7022
Unlock CFMS Revenue
Relative Strength (%)
1m +56.1%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -2.96%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
66.9 79.9 78.1 89.8 77.4 68.8 84.5 79.0 +0.6%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, ConforMISInc revenues decreased 16% to $13.8M. Net loss increased23% to $11.5M. Revenues reflect United States segmentdecrease of 16% to $11.6M, Germany segment decrease of 10%to $1.8M. Higher net loss reflects foreign currencyexchange increase from $714K to $1.8M (expense), Generaland administrative - Other increase of 17% to $6.1M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CFMS Revenue Unlock CFMS Revenue

Net Income

CFMS Net Income Unlock CFMS Revenue

Normalised EPS

CFMS Normalised EPS Unlock CFMS Revenue

PE Ratio Range

CFMS PE Ratio Range Unlock CFMS Revenue

Dividend Yield Range

CFMS Dividend Yield Range Unlock CFMS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CFMS EPS Forecasts Unlock CFMS Revenue
Profile Summary

ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient's anatomy. The Company's iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient's knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated March 26, 2004
Public Since July 1, 2015
No. of Shareholders: 287
No. of Employees: 259
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 182,476,224
Free Float (0.0%)
Eligible for
CFMS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CFMS
Upcoming Events for CFMS
Wednesday 4th August, 2021
Q2 2021 Conformis Inc Earnings Release
Wednesday 4th August, 2021
Q2 2021 Conformis Inc Earnings Call
Wednesday 11th August, 2021
Conformis Inc at Canaccord Genuity Growth Conference (Virtual)
Tuesday 2nd November, 2021 Estimate
Q3 2021 Conformis Inc Earnings Release
Frequently Asked Questions for Conformis Inc
What is the Conformis Inc share price?

As of 04/08/21, shares in Conformis Inc are trading at $1.53, giving the company a market capitalisation of £215.1m. This share price information is delayed by 15 minutes.

How has the Conformis Inc share price performed this year?

Shares in Conformis Inc are currently trading at $1.53 and the price has moved by 0.116k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Conformis Inc price has moved by 62.74% over the past year.

What are the analyst and broker recommendations for Conformis Inc?

Of the analysts with advisory recommendations for Conformis Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Conformis Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Conformis Inc next release its financial results?

Conformis Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Conformis Inc dividend yield?

Conformis Inc does not currently pay a dividend.

Does Conformis Inc pay a dividend?

Conformis Inc does not currently pay a dividend.

When does Conformis Inc next pay dividends?

Conformis Inc does not currently pay a dividend.

How do I buy Conformis Inc shares?

To buy shares in Conformis Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Conformis Inc?

Shares in Conformis Inc are currently trading at $1.53, giving the company a market capitalisation of £215.1m.

Where are Conformis Inc shares listed? Where are Conformis Inc shares listed?

Here are the trading details for Conformis Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CFMS
What kind of share is Conformis Inc?

Based on an overall assessment of its quality, value and momentum, Conformis Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Conformis Inc share price forecast 2021?

Shares in Conformis Inc are currently priced at $1.53. At that level they are trading at 42.07% discount to the analyst consensus target price of 0.00.

Analysts covering Conformis Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.167 for the next financial year.

How can I tell whether the Conformis Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Conformis Inc. Over the past six months, the relative strength of its shares against the market has been 26.35%. At the current price of $1.53, shares in Conformis Inc are trading at 72.87% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Conformis Inc PE Ratio?

We were not able to find PE ratio data for Conformis Inc.

Who are the key directors of Conformis Inc?

Conformis Inc's management team is headed by:

Kenneth Fallon - NEC
Bradley Langdale - IND
Richard Meelia - IND
Mark Augusti - PRE
Carrie Bienkowski - IND
Philip Johnston - IND
Robert Howe - CFO
J. Brent Alldredge - SEC
Who are the major shareholders of Conformis Inc?

Here are the top five shareholders of Conformis Inc based on the size of their shareholding:

Wasatch Global Investors Inc Investment Advisor/Hedge Fund
Percentage owned: 9.71% (17.7m shares)
Wasatch Ultra Growth Fund Mutual Fund
Percentage owned: 7.66% (14.0m shares)
Consonance Capital Management LP Hedge Fund
Percentage owned: 7.12% (13.0m shares)
Armistice Capital LLC Hedge Fund
Percentage owned: 5.23% (9.54m shares)
Stonepine Capital Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 5.02% (9.16m shares)
Similar to CFMS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.